Linagliptin

CAS 668270-12-0 30 current records 1 historicalSmall Molecule

Who holds supplier records for Linagliptin? 30 organisations hold a current record for Linagliptin: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 1 of them holds a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (20), China (5), Netherlands (1) and Poland (1); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Linagliptin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/linagliptin

Reading the evidence

  • 30 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    20 of the 27 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 17 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Linagliptin expires 8 Dec 2037. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (30)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Linagliptin. Country is the organisation's recorded country, not necessarily the manufacturing site.

India20China5Netherlands1Poland1Country not recorded for 3
Need Linagliptin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (1)

Certificates of Suitability on the EDQM register for Linagliptin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. TaizhouCN
CEP 2026-380 - Rev 00
Linagliptin, Process II, micronised and non-micronised
Sept 2026Inspected May 2026
Italy

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Linagliptin are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • Viwit Pharmaceutical Co., Ltd.
    China · Inactive DMF 29692 · filed Aug 2015

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (9 listed products contain Linagliptin). The latest listed patent expires 8 Dec 2037. The latest listed exclusivity runs to 20 Dec 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor used as an oral hypoglycemic agent for the treatment of type 2 diabetes. It works by increasing the levels of incretin hormones, which inhibit glucagon release and increase insulin secretion.

Chemical identity

IUPAC name
8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
Canonical SMILES
CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
InChIKey
LTXREWYXXSTFRX-QGZVFWFLSA-N
Synonyms
bi 1356, bi 1356 bs, bi-1356, bi-1356-bs, bi-1356bs, bi1356, bs 1356 bs, bs-1356-bs, glyxambi component linagliptin, trajenta, trazenta, trijardy xr component linagliptin

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor
Mechanism of action
Dipeptidyl Peptidase 4 Inhibitors

Therapeutic areas

EndocrinologyMetabolic Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Linagliptin?

30 organisations hold an active US FDA Type II Drug Master File or a CEP for Linagliptin: Alembic Pharmaceuticals Limited (India), Biocon Limited (India), HONOUR LAB LTD (India), MSN PHARMACHEM PRIVATE LTD (India), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), ALIVUS LIFE SCIENCES LTD (India), APITORIA PHARMA PRIVATE LTD (India) and BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (China), and 22 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Linagliptin Drug Master Files are active?

Alembic Pharmaceuticals Limited (DMF 31452, 43882), Biocon Limited (DMF 35771, 41475), HONOUR LAB LTD (DMF 28877, 28878), MSN PHARMACHEM PRIVATE LTD (DMF 28098, 42033), Zhejiang Huahai Pharmaceutical Co., Ltd. (DMF 28766), ALIVUS LIFE SCIENCES LTD (DMF 27907), APITORIA PHARMA PRIVATE LTD (DMF 28940) and BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (DMF 28404) and 22 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Linagliptin records mean?

1 organisation has only inactive Type II DMFs for Linagliptin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Linagliptin have a European Certificate of Suitability?

Yes. 1 organisation holds a valid CEP for Linagliptin on the EDQM register, including ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Taizhou (CN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Linagliptin?

Yes. The latest patent listed for an approved US product containing Linagliptin expires 8 Dec 2037, across 9 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Linagliptin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Linagliptin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.